GBP4: A Potential Drug Target and Biomarker (G115361)

Target Name: GBP4

NCBI ID: G115361

GBP4

GBP4: A Potential Drug Target and Biomarker

Guanine nucleotide-binding proteins (GBPs) are a family of transmembrane proteins that play a crucial role in various cellular processes, including DNA replication, repair, and metabolism. One of the GBP families, GBP4, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases.

GBP4 is a 21-kDa protein that is expressed in various tissues and cells, including brain, heart, liver, and pancreatic cancer cells. It is composed of a 156 amino acid long N-terminus, a 234 amino acid long catalytic domain, and a 32 amino acid long C-terminus. GBP4 functions as a nucleotide-binding protein by binding to guanine nucleotides in various DNA and RNA molecules.

The guanine nucleotide is a crucial molecule in life, as it is the genetic unit of DNA replication and repair. GBP4 is involved in the regulation of DNA replication, specifically in the process of DNA double-strand break repair. GBP4 plays a critical role in repairing double-strand breaks in damaged DNA by binding to the complementary DNA strand and facilitating the formation of a new double-strand.

In addition to its role in DNA repair, GBP4 is also involved in the regulation of DNA metabolism, including the replication, transcription, and translation of DNA information. GBP4 has been shown to play a role in the regulation of DNA replication, specifically in the G1 phase of the cell cycle. In G1, GBP4 binds to the G1-specific transcription factor p21 and enhances the binding of p21 to its DNA target, leading to increased DNA replication and gene expression.

GBP4 has also been shown to play a role in neurodegenerative diseases. GBP4 is expressed in various tissues and has been implicated in the development and progression of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. GBP4 has been shown to interact with neurotransmitters, including dopamine, and to modulate the expression of genes involved in neurotransmitter synthesis and function.

Furthermore, GBP4 has also been shown to be involved in cardiovascular diseases. GBP4 is expressed in various tissues and has been implicated in the development and progression of cardiovascular diseases, including heart failure, hypertension, and angina. GBP4 has been shown to interact with angiotensin II, a hormone that contributes to cardiovascular disease, and to modulate the expression of genes involved in stress response and inflammation.

In conclusion, GBP4 is a protein that plays a critical role in various cellular processes, including DNA replication, repair, and metabolism. GBP4 is also involved in the regulation of DNA metabolism, neurodegenerative diseases, and cardiovascular diseases. Therefore, GBP4 is a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases.

Protein Name: Guanylate Binding Protein 4

Functions: Interferon (IFN)-inducible GTPase that plays important roles in innate immunity against a diverse range of bacterial, viral and protozoan pathogens (By similarity). Negatively regulates the antiviral response by inhibiting activation of IRF7 transcription factor (By similarity)

The "GBP4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GBP4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets